Business
ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug
ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating No...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"\n\n\nZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\nEarly Data Suggests a Trend Toward Improvement in Pain Efficacy\nSASKATOON, SK, Jan. 8, 2026 /CNW/ - ZYUS Life Sciences Corporation (the \"Company\") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.\n\n\n\n\n\n\n\nPreliminary Results Highlights\nUTOPIA-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.\nPreliminary results from the Phase 2a are based on the data from the first 25% of enrolled patients who have completed treatment in the UTOPIA-1 trial. Early data suggest:\nReduction in average daily pain, pain interference, and pain severity.Reduction in opioid dosing for breakthrough pain.No serious adverse events related to Trichomylin® softgel capsules.Trichomylin® softgel capsules were generally well tolerated, with the majority of adverse reactions being expected, mild, and occurring during dose titration, consistent with the Company's Phase 1 Z-TRI-10001 trial (NCT04867057).\"This is an important milestone, as it allows us to assess early outcomes from the first cohort of five patients who have completed treatment and further validates our clinical trial design in this challenging patient population\" said Dr. Julie Stakiw, Chief Medical Officer of ZYUS. \"These results provide initial insight into the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules as the...